AVEO Oncology

AVEO Oncology is a commercial-stage, oncology-focused biopharmaceutical company established in 2001. The company's slogan, "Committed to delivering medicines that provide a better life for patients with cancer," reflects its dedication to improving the lives of cancer patients. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. Furthermore, AVEO is actively involved in developing FOTIVDA in immuno-oncology combinations in RCC and other indications, in addition to having other investigational programs in clinical development. Notably, AVEO is committed to fostering diversity, equity, and inclusion within the company. The most recent investment in AVEO Oncology was a Post-IPO Equity investment on 22 March 2021. Although details about the specific investors are not provided, the company's focus on oncology and its track record in delivering medicines for cancer patients underscore its appeal to potential venture capital interests.